Holen Sie sich die Stockscreener-App
172.99
0.76%
1.31
Handel nachbörslich:
174.20
1.21
+0.70%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$171.68
Offen:
$172.57
24-Stunden-Volumen:
8.47M
Relative Volume:
1.22
Marktkapitalisierung:
$316.82B
Einnahmen:
$56.33B
Nettoeinkommen (Verlust:
$4.28B
KGV:
72.08
EPS:
2.4
Netto-Cashflow:
$17.83B
1W Leistung:
-0.69%
1M Leistung:
-19.34%
6M Leistung:
-8.26%
1J Leistung:
+5.32%
1-Tages-Spanne:
$171.91
$175.20
1-Wochen-Bereich:
$169.33
$180.50
52-Wochen-Spanne:
$153.58
$218.66
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Vergleichen Sie ABBV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
172.99 | 316.82B | 56.33B | 4.28B | 17.83B | 2.40 |
|
LLY
Lilly Eli Co
|
839.96 | 677.40B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
157.47 | 371.98B | 89.33B | 21.81B | 18.06B | 8.99 |
|
NVO
Novo Nordisk Adr
|
58.08 | 293.24B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
110.86 | 216.19B | 51.72B | 11.94B | 13.81B | 5.88 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TradingView
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights – ABBV - TradingView
Is AbbVie Inc. (ABBV) the Best Large-Cap Value Stock to Buy as the Recession Hits? - Insider Monkey
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - MarketScreener
Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market - GlobeNewswire Inc.
AbbVie (ABBV): A Top Dividend Monarch with Strong Growth Prospects - GuruFocus
Applications now open for Abbvie’s cystic fibrosis scholarship program - Cystic Fibrosis News Today
AbbVie (ABBV) Gets a Buy from Guggenheim - The Globe and Mail
Fund Update: Bank Pictet & Cie (Europe) AG added 78,930 shares of ABBVIE ($ABBV) to their portfolio - Nasdaq
AbbVie Inc. (ABBV): Among the Innovative Healthcare Stocks to Watch in 2025 - Yahoo Finance
ABBV LAWSUIT ALERT: The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MarketScreener
AbbVie Inc. (ABBV) Stock Forecasts - Yahoo Finance
10 Innovative Healthcare Stocks to Watch in 2025 - Insider Monkey
AbbVie Inc. (ABBV): One of the Best Dividend Monarchs to Invest in Now - Insider Monkey
Interleukin Inhibitors Market Is Booming Worldwide | AbbVie - openPR.com
Drug company files suit against South Dakota over new 340B law - South Dakota Public Broadcasting
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks - Yahoo Finance
The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment - Nasdaq
Top Research Reports for AbbVie, TJX & Charles Schwab - MSN
AbbVie Asks Court to Extend Venclexta Cancer-Drug Patent’s Life - Bloomberg Law News
AbbVie Options Trading: A Deep Dive into Market Sentiment - Nasdaq
AbbVie Inc. (ABBV): One of the High Growth Forever Dividend Stocks to Invest In - Yahoo Finance
Drugmaker sues SD over law preserving broad access to discounts for hospitals, pharmacies - Argus Leader
The Zacks Analyst Blog Merck and AbbVie - TradingView
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
AbbVie and Sandoz agree to drop court spat over Rinvoq patents - Endpoints News
ABBV vs. MRK: Which Drug Giant is a Better Buy Now? - Yahoo Finance
Arthralgia Market to Reach New Heights in Growth by 2032, - openPR.com
The Zacks Analyst Blog Merck And AbbVie - Barchart.com
Meta, TJX, Taiwan Semiconductor Manufacturing And A Health Care Stock: CNBC's 'Final Trades' - Benzinga
Earnings Preview: What to Expect From AbbVie's Report - Nasdaq
Earnings Preview: What To Expect From AbbVie's Report - Barchart.com
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis - Yahoo Finance
10 High Growth Forever Dividend Stocks To Invest In - Insider Monkey
Is AbbVie Inc. (ABBV) the Best Stock for 15 Years? - Yahoo Finance
Skin Boosters Market to Witness Stunning Growth with AbbVie, Medytox, ExoCoBio - openPR.com
AbbVie (ABBV) Faces Volatility Despite Positive Earnings in Q1 2 - GuruFocus
AbbVie, Sandoz Settle Patent Fight Over Rinvoq Generics - Law360
Multiple Myeloma Pipeline 2025: Latest FDA Approvals, Clinical - openPR.com
AbbVie Unusual Options Activity - Benzinga
AbbVie (NYSE:ABBV) Shares Down 5.6%Should You Sell? - MarketBeat
AbbVie Aesthetics Line Faces Potential Risk in Current Macro Environment, UBS Says - MarketScreener
AbbVie Brings New Suits Against State Pharmacy Contract Laws - Bloomberg Law News
Pharma Stock Roundup: EU Nod to Expanded Use of ABBV, AZN Drugs & More - TradingView
Ex-Dividend Reminder: Buckle, AbbVie and Abbott Laboratories - Nasdaq
Here’s Why Clearbridge Growth Strategy Sold AbbVie (ABBV) - Insider Monkey
ABBV Stock Upgraded to Buy Amid Valuation Insights - GuruFocus
AbbVie Files Lawsuits to Block Drug Pricing Laws in North Dakota and South Dakota - USA Herald
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
7.63%
2.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):